Table 1.
Demographic, clinical and laboratory findings in groups I and II
| 2000–2015 | 2000–2012 (inpatients) | 2012–2015 (outpatients) | p Value | |
| Biopsies | 462 | 333 | 129 | |
| Passages, mean±SD/median (range) | 2.6±0.7/3 (1–5) | 2.9±0.6/3 (1–5) | 3.1±0.6/3 (2–5) | NS |
| Glomeruli, mean±SD/median (range) | 19.9±11.3/18 (6–71) | 21.6±12.4/20 (1–71) | 23.9±12/23 (3–58) | 0.01 |
| Age, mean±SD | 54.7±17.9 | 56±19 | 52±17.6 | NS |
| Female, n (%) | 180 (39) | 114 (34) | 66 (51) | NS |
| Admission duration (days), mean±SD/median (range) | – | 1.1±0.6/1 (1–7) | – | |
| sCr (mg/dL), mean±SD/median (range) | 1.67±1.2/1.3 (0.5–7) | 1.56±0.9/1.3 (0.5–6) | 1.8±1.24/1.4 (0.5–7) | NS |
| sCr >3 (mg/dL), n (%) | 124 (26.8) | 89 (29.6) | 35 (27.1) | NS |
| Proteinuria (g/24 hours), mean±SD/median (range) | 2.6±2.3/2 (0.0–13) | 2.7±2.2/2 (0.0–10) | 2.6±2.2/2 (0.2–13) | NS |
| Prebiopsy haematuria, n (%) | 375 (81.2) | 261 (78.4) | 114 (88.4) | 0.01 |
| Resistant hypertension*, n (%) | 110 (23.9) | 93 (27.9) | 17 (13.2) | 0.008 |
| Complications (any), n (%) | 36 (7.8) | 24 (7.2) | 12 (9.3) | NS |
| Minor, n (%) | 27 (5.8) | 19 (5.7) | 8 (6.2) | NS |
| Major, n (%) | 9 (1.9) | 5 (1.5) | 4 (3.1) | NS |
*Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281–357.